Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oxyforte LX
- Development stage
- Unknown
- Lead developer
- Jainson Biotech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Oxyforte LX is an oral dietary supplement developed by Jainson Biotech, specifically formulated to support eye health, boost immunity, and maintain antioxidant balance. It is indicated for preventing the progression of age-related macular degeneration (AMD) and reducing the risk of cataracts. The formulation contains a synergistic blend of free lutein, zeaxanthin, essential vitamins (Vitamin A, Vitamin C, Vitamin E), and key minerals (zinc, selenium, copper). These components function as potent antioxidants and macular pigments, filtering harmful blue light and neutralizing free radicals to protect retinal tissues from oxidative damage.
- Brand names
- Oxyforte LXOxyforte-LX
- Other names
- copper + lutein + selenium + vitamin A + vitamin C + vitamin E + zeaxanthin + zinc
Beyond the preview
Go deeper on Oxyforte LX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oxyforte LX.